People · Operator
Named in public records as an officer, director or promoter · active 2012–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Good Start Genetics, Inc. | — | Biotechnology | Series B | $28.2M | $396.9M | 2012 |
| GeneCentric Therapeutics, Inc. | — | Biotechnology | Series A | $21.6M | $6.7M | 2025 |
Don Hardison at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Don Hardison on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Carl Gordon | 1 | 24 |
| Clay Thorp | 1 | 10 |
| Gary Kurtzman | 1 | 8 |
| Lutz Giebel | 1 | 6 |
| Robert Carpenter | 1 | 5 |
| Arnold Levine | 1 | 4 |
| Marc Beer | 1 | 4 |
| Robert J. Carpenter | 1 | 3 |
| Michael Milburn | 1 | 3 |
| Ellen Lubman | 1 | 2 |
| Myla Lai-Goldman | 1 | 2 |
| CARL J. GORDON | 1 | 2 |
| Clay Neil Thorp | 1 | 1 |
| Charles Neil Perou | 1 | 1 |
| David Neil Hayes | 1 | 1 |
| CHARLES PEROU | 1 | 1 |
| Prasanth Reddy | 1 | 1 |
| Ellen V. Lubman | 1 | 1 |
| Michael V. Milburn | 1 | 1 |
| Perou V. Charles | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.